Strategic Partnership with Toshiba

RNS Number : 0928P

Advanced Oncotherapy PLC

14 August 2014

 



14 August 2014

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Toshiba and Advanced Oncotherapy sign a strategic supply partnership

       Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton-radiation therapy,is delighted to announce a 5-year agreement with Toshiba Electron Tubes & Devices Co., Ltd., Japan ("Toshiba"). As part of this collaboration, Toshiba will provide the Klystron for the Advanced Oncotherapy LIGHT machine.  The Klystron - a wave-based particle accelerator component - is a central part of the LIGHT machine, allowing protons to be accelerated at high speed before the energy is released into the patient's body, subsequently causing damage and killing cancer cells. 

Toshiba is a world-class leader in a range of fields, including electronics, specialist electronics and medically-related electronic applications.

Seiji Tanaka, General Manager of Sales, Toshiba Electron Tubes & Devices Co., Ltd. commented: "We are very pleased to sign this win-win partnership with Advanced Oncotherapy. We have been following the Advanced Oncotherapy story very closely and that has given us confidence that our new partner is uniquely positioned to bring to the market a truly revolutionary and game-changing treatment. We are committed to help Advanced Oncotherapy realise its objectives." 

Julian Tokuta, Head of Procurement for Advanced Oncotherapy commented: "Toshiba brings demonstrated capabilities in manufacturing highly specialised components as well as a clear ability to scale up production and meet the expected demand in the proton treatment market for Advanced Oncotherapy LIGHT machines. In addition, Toshiba already has a longstanding relationship with ScandiNova who we recently signed a contract with, giving us two very strong partners to build a core element of the LIGHT machine."

Commenting on this partnership, Sanjeev Pandya, CEO of Advanced Oncotherapy said: "I am really delighted to have Toshiba - a world-class provider in particle-accelerator components - as one of our partners and I look forward to our collaboration throughout our developmental roadmap. This agreement demonstrates our unique commitment to work with established leaders who will provide quality components required for the successful development of the next generation of particle therapy systems. This collaboration will also give further confidence to patients, customers and shareholders that Advanced Oncotherapy is committed to choose the right path and to deliver a new system that requires neither the massive infrastructure, shielding nor extensive capital outlay of older and current forms of proton accelerators." 

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya (CEO)	Tel: [phone]
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson	Tel: [phone]
Walbrook PR (Financial PR & IR)	[e-mail]
Anna Dunphy / Mike Wort	Tel: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

For more information, please visit http://www.avoplc.com

 

END

 

 

AGRLIFVFTRISLIS